Durata Therapeutics Closes Public Offering of Common Stock
CHICAGO, April 17, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc.
(Nasdaq:DRTX) today announced the closing of its public offering of 8,222,500
shares of common stock at a public offering price of $7.00 per share, before
underwriting discounts, including 1,072,500 shares of common stock issued upon
the exercise in full by the underwriters of their option to purchase
additional shares at the public offering price less the underwriting discount.
BofA Merrill Lynch, Credit Suisse Securities (USA) LLC and JefferiesLLC acted
as joint book-running managers for the offering, and JMP Securities LLC and
RBC Capital Markets, LLC acted as co-managers.
A registration statement relating to the securities sold in this offering was
declared effective by the Securities and Exchange Commission on April11,
2013. Copies of the final prospectus relating to this offering may be obtained
by contacting BofA Merrill Lynch by mail at 222Broadway, New York, NY 10038,
Attn: Prospectus Department, or by e-mail at email@example.com;
Credit Suisse Securities (USA) LLC by mail at One Madison Avenue, New York, NY
10010, Attn: Prospectus Department, by e-mail at
firstname.lastname@example.org, or by telephone at 1-800-221-1037; or
JefferiesLLC by mail at 520 Madison Avenue, New York, New York 10022,
Attn:Equity Syndicate Prospectus Department, by e-mail at
Prospectus_Department@Jefferies.com, or by telephone at 1-877-547-6340.
This press release shall not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of, these securities in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities laws
of such state or jurisdiction.
About Durata Therapeutics
Durata Therapeutics is a pharmaceutical company focused on the development and
commercialization of novel therapeutics for patients with infectious diseases
and acute illnesses. Durata has completed two global Phase 3 clinical trials
with its lead product candidate, dalbavancin, under investigation for the
treatment of patients with acute bacterial skin and skin structure infections
caused by susceptible gram-positive bacteria.
CONTACT: Allison Wey
Durata Therapeutics, Inc.
Vice President, Investor Relations and Public Affairs
Durata Therapeutics, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.